META-ANALYSIS ON THE EFFICACY AND SAFETY OF BELIMUMAB FOR LUPUS NEPHRITIS BY USING THE PUBMED DATABASE

IF 1.4 4区医学 Q4 PHARMACOLOGY & PHARMACY

FARMACIA Pub Date : 2023-10-26 DOI:10.31925/farmacia.2023.5.2

QIYUAN CHEN

{"title":"META-ANALYSIS ON THE EFFICACY AND SAFETY OF BELIMUMAB FOR LUPUS NEPHRITIS BY USING THE PUBMED DATABASE","authors":"QIYUAN CHEN","doi":"10.31925/farmacia.2023.5.2","DOIUrl":null,"url":null,"abstract":"Systemic lupus erythematosus (SLE) is a chronic autoimmune connective tissue disease associated with loss of immunological tolerance (LIT). Lupus nephritis (LN) is a serious manifestation of SLE, affecting the majority of patients and posing a significant threat to the well-being and survival of SLE patients. More research and evidence are needed to determine whether belimumab can be used to treat active LN, as data on the safety and efficacy of belimumab in the treatment of active LN are currently lacking. The search criteria utilised were “belimumab”, “lupus nephritis”, “systemic lupus erythematosus” and “lupus treatment”. The search was limited to articles published between January 2000 and May 2022. The analysis and evaluation were performed using Rev Man 5.3 and Stata, the risk of bias (RoB) of the included articles was assessed, and the heterogeneity was assessed using the Q-test and the I2 statistics. The results showed that in the 6 included references, the OR for efficacy of belimumab in the treatment of LN was 0.30, the OR for safety was 0.22, and no heterogeneity was observed between study groups (I2 = 0.00%; I2 = 0.00%). The OR for renal involvement of belimumab in the treatment of LN was - 0.22, and the OR for complications was -0.37, indicating apparent heterogeneity","PeriodicalId":12344,"journal":{"name":"FARMACIA","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"FARMACIA","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.31925/farmacia.2023.5.2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune connective tissue disease associated with loss of immunological tolerance (LIT). Lupus nephritis (LN) is a serious manifestation of SLE, affecting the majority of patients and posing a significant threat to the well-being and survival of SLE patients. More research and evidence are needed to determine whether belimumab can be used to treat active LN, as data on the safety and efficacy of belimumab in the treatment of active LN are currently lacking. The search criteria utilised were “belimumab”, “lupus nephritis”, “systemic lupus erythematosus” and “lupus treatment”. The search was limited to articles published between January 2000 and May 2022. The analysis and evaluation were performed using Rev Man 5.3 and Stata, the risk of bias (RoB) of the included articles was assessed, and the heterogeneity was assessed using the Q-test and the I2 statistics. The results showed that in the 6 included references, the OR for efficacy of belimumab in the treatment of LN was 0.30, the OR for safety was 0.22, and no heterogeneity was observed between study groups (I2 = 0.00%; I2 = 0.00%). The OR for renal involvement of belimumab in the treatment of LN was - 0.22, and the OR for complications was -0.37, indicating apparent heterogeneity

查看原文本刊更多论文

利用 Pubmed 数据库对贝利木单抗治疗狼疮肾炎的疗效和安全性进行荟萃分析

系统性红斑狼疮（SLE）是一种与免疫耐受丧失（LIT）相关的慢性自身免疫性结缔组织疾病。狼疮性肾炎（LN）是系统性红斑狼疮的一种严重表现，影响着大多数患者，并对系统性红斑狼疮患者的福祉和生存构成重大威胁。由于目前缺乏有关贝利木单抗治疗活动性LN的安全性和有效性的数据，因此需要更多的研究和证据来确定贝利木单抗是否可用于治疗活动性LN。检索标准为 "贝利木单抗"、"狼疮肾炎"、"系统性红斑狼疮 "和 "狼疮治疗"。检索仅限于2000年1月至2022年5月期间发表的文章。使用Rev Man 5.3和Stata进行了分析和评估，评估了纳入文章的偏倚风险（RoB），并使用Q检验和I2统计量评估了异质性。结果显示，在纳入的6篇参考文献中，贝利木单抗治疗LN的疗效OR值为0.30，安全性OR值为0.22，研究组间未观察到异质性（I2 = 0.00%；I2 = 0.00%）。贝利木单抗治疗LN时肾脏受累的OR值为- 0.22，并发症的OR值为-0.37，表明存在明显的异质性

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

FARMACIA 医学-药学

CiteScore

2.40

自引率

50.00%

发文量

审稿时长

6-12 weeks

期刊介绍： FARMACIA publishes original research papers, invited topical reviews and editorial commentaries and news, with emphasis on conceptual novelty and scientific quality. Main research areas are focused on: pharmacology, toxicology, medicinal chemistry, biopharmacy, drug design, drug delivery, personalized medicine, nanostructures, nutraceuticals, biochemistry and biotechnology. Manuscripts submitted to the Journal are only accepted after the peer review precess. The papers should have not been published in any other journal. The recommendations of the Declaration of Helsinki, for humans, and the International guidelines as accepted principles for the use of experimental animals should be followed.